Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

JUERGENS

Showing results (591-600 of 662) with videos related to

Pageof 67
Sort By:
European Journal of Cancer (Oxford, England : 1990)|August 15, 2015
Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: secondary analysis of the Euro-Ewing99-R1 trialHenk van den Berg, Michael Paulussen, Gwénaël Le Teuff, et al.
Investigational New Drugs|February 6, 2020
A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignanciesJ Nehra, P A Bradbury, P M Ellis, et al.
Pediatric Blood & Cancer|June 6, 2013
Effective childhood cancer treatment: the impact of large scale clinical trials in Germany and AustriaC Rossig, H Juergens, M Schrappe, et al.
European Journal of Cancer (Oxford, England : 1990)|February 26, 2008
Microarray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapyKarl-Ludwig Schaefer, Martin Eisenacher, Yvonne Braun, et al.
Current Oncology (Toronto, Ont.)|June 23, 2016
Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancerB Melosky, J Agulnik, R Albadine, et al.
Annals of the Rheumatic Diseases|June 2, 2025
Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 studyPeter C Taylor, Philip J Mease, Kurt de Vlam, et al.
Open Heart|April 9, 2026
Sex differences in risk factor control and medication adherence post-ACS: insights from the TEXTMEDS randomised clinical trialShiva Raj Mishra, Simone Marschner, Haeri Min, et al.
EJNMMI Research|January 20, 2017
A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB-IIIA resectable NSCLCJohn P Crandall, Abdel K Tahari, Rosalyn A Juergens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2009
Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adultsTobias M Dantonello, Christoph Int-Veen, Dieter Harms, et al.
Cancer Discovery|May 16, 2012
Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancerRosalyn A Juergens, John Wrangle, Frank P Vendetti, et al.
Pageof 67

Showing results (591-600 of 662) with videos related to

Sort By:
Pageof 67
European Journal of Cancer (Oxford, England : 1990)|August 15, 2015
Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: secondary analysis of the Euro-Ewing99-R1 trialHenk van den Berg, Michael Paulussen, Gwénaël Le Teuff, et al.
Investigational New Drugs|February 6, 2020
A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignanciesJ Nehra, P A Bradbury, P M Ellis, et al.
Pediatric Blood & Cancer|June 6, 2013
Effective childhood cancer treatment: the impact of large scale clinical trials in Germany and AustriaC Rossig, H Juergens, M Schrappe, et al.
European Journal of Cancer (Oxford, England : 1990)|February 26, 2008
Microarray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapyKarl-Ludwig Schaefer, Martin Eisenacher, Yvonne Braun, et al.
Current Oncology (Toronto, Ont.)|June 23, 2016
Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancerB Melosky, J Agulnik, R Albadine, et al.
Annals of the Rheumatic Diseases|June 2, 2025
Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 studyPeter C Taylor, Philip J Mease, Kurt de Vlam, et al.
Open Heart|April 9, 2026
Sex differences in risk factor control and medication adherence post-ACS: insights from the TEXTMEDS randomised clinical trialShiva Raj Mishra, Simone Marschner, Haeri Min, et al.
EJNMMI Research|January 20, 2017
A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB-IIIA resectable NSCLCJohn P Crandall, Abdel K Tahari, Rosalyn A Juergens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2009
Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adultsTobias M Dantonello, Christoph Int-Veen, Dieter Harms, et al.
Cancer Discovery|May 16, 2012
Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancerRosalyn A Juergens, John Wrangle, Frank P Vendetti, et al.
Pageof 67